{
    "clinical_study": {
        "@rank": "62147", 
        "arm_group": {
            "arm_group_label": "Study Group", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive one booster dose of SP059 (IMOVAX POLIO\u00ae)"
        }, 
        "brief_summary": {
            "textblock": "The aim of the study is to assess the immunogenicity of SP059 (IMOVAX POLIO\u00ae: Inactive\n      Poliovirus Vaccine) vaccine against poliovirus and safety after fifth dose.\n\n      Primary Objective:\n\n        -  To investigate the booster vaccine response rate against poliovirus types 1, 2 and 3\n           one month following the vaccination dose with SP059 as 2nd booster\n\n      Secondary Objectives:\n\n        -  To investigate seroprotection rates (percentage of subjects presenting poliovirus\n           neutralizing antibody titers above 1:8 (1/dil.) at pre- and post-booster time points,\n           Geometric mean titers (GMT) at pre- and post-booster time points and geometric mean of\n           individual titer ratio (GMTR).\n\n        -  To investigate the safety after dosing of SP059 as 2nd booster."
        }, 
        "brief_title": "Study of IMOVAX POLIO\u00ae Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Poliomyelitis", 
            "Polio"
        ], 
        "condition_browse": {
            "mesh_term": "Poliomyelitis"
        }, 
        "detailed_description": {
            "textblock": "Participants will receive one dose of SP059 (at Visit 1) as a booster vaccination at an age\n      from 4 to 6 years. They will be assessed for immunogenicity at baseline (pre-vaccination)\n      and at 4-6 weeks post- vaccination.\n\n      Safety data including serious adverse events (SAEs) after vaccination will be collected\n      during the study period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged 4 to 6 years inclusive on the day of inclusion\n\n          -  Subjects who received 4 times an IPV-containing vaccine (DTaP-IPV or IPV) during\n             first (3 doses) and second year of life (one dose)\n\n          -  Informed consent form signed by the parent(s) or other legal representative\n\n          -  Able to attend all scheduled visits and to comply with all trial procedures.\n\n        Exclusion Criteria:\n\n          -  Fever \u2265 37.5\u00b0C (axillary temperature) on the day of inclusion\n\n          -  Any serious disease whether acute or chronic\n\n          -  Past or current medical history of Guillain-Barre syndrome, acute thrombocytopenic\n             purpura or encephalopathy\n\n          -  History of poliomyelitis infection\n\n          -  History of a life threatening reaction to a vaccine containing the same substances of\n             the study vaccine\n\n          -  History of anaphylaxis or allergy to any of the study vaccine components\n\n          -  Congenital or current/previous acquired immunodeficiency, immunosuppressive therapy\n             such as long-term systemic corticosteroids therapy\n\n          -  Participation in another clinical trial within 6 months before the trial inclusion\n\n          -  Planned participation in another clinical trial during the present trial period\n\n          -  Received oral or injected antibiotic therapy within the 72 hours prior to any blood\n             draw\n\n          -  Received antipyretics/analgesics/Non-steroidal anti-inflammatory drugs (considered as\n             a single category) within 4 hours prior to vaccination\n\n          -  Blood or blood-derived products received in the past or current or planned\n             administration during the trial (including immunoglobulins)\n\n          -  Any vaccination with live vaccines within the past 27 days preceding the trial\n             vaccination\n\n          -  Any vaccination with inactivated vaccines within the past 6 days preceding the trial\n             vaccination\n\n          -  Clinical or known serological evidence of systemic illness including Hepatitis B,\n             Hepatitis C and/or HIV infection\n\n          -  Subject ineligible according to the Investigator's clinical judgment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "6 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005536", 
            "org_study_id": "IPV46 (EFC13614)", 
            "secondary_id": "U1111-1143-8561"
        }, 
        "intervention": {
            "arm_group_label": "Study Group", 
            "description": "0.5 mL, Subcutaneous", 
            "intervention_name": "IMOVAX POLIO\u00ae: Inactive Poliovirus Vaccine", 
            "intervention_type": "Biological", 
            "other_name": [
                "SP059", 
                "IMOVAX POLIO\u00ae"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Poliomyelitis", 
            "Poliovirus", 
            "Polio", 
            "IMOVAX POLIO\u00ae", 
            "Inactivated polio vaccine"
        ], 
        "lastchanged_date": "December 6, 2013", 
        "link": [
            {
                "url": "http://www.sanofipasteur.com"
            }, 
            {
                "url": "http://www.sanofi.com"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mie", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Immunogenicity and Safety of IMOVAX POLIO\u00ae Subcutaneous as a Booster Given in Pre-school Age Children in Japan", 
        "overall_contact": {
            "email": "RegistryContactUs@sanofipasteur.com", 
            "last_name": "Public Registry Sanofi Pasteur"
        }, 
        "overall_official": {
            "affiliation": "Sanofi K.K.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Anti-Poliovirus types 1, 2, and 3 titers will be measured by neutralization assay.", 
            "measure": "Percentage of participants with at least a four-fold rise in anti-Polio 1, 2 and 3 antibody titers between the pre-booster and one month after the dose of IPV", 
            "safety_issue": "No", 
            "time_frame": "Day 0 (pre-) and 28 post-booster vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005536"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Solicited injection site: Pain, Redness, and Swelling. Solicited Systemic reaction: Fever (Temperature), Headache, Malaise, and Myalgia; Unsolicited Adverse Event (AE) defined as an observed AE that does not fulfill the conditions pre-listed in the case report form. Serious adverse event defined as: Death, Life threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability incapacity,", 
                "measure": "Description of the safety profile in terms of solicited injection-site and systemic reactions, unsolicited adverse events and serious adverse events after a vaccination with IPV", 
                "safety_issue": "No", 
                "time_frame": "Day 0 up to Day 28 post-booster vaccination"
            }, 
            {
                "description": "Anti-Poliovirus types 1, 2, and 3 titers will be measured by neutralization assay.", 
                "measure": "Immunogenicity in terms of percentage of participants with anti-Polio 1, 2, and 3 titers \u2265 8 [1/dilution], Geometric Mean Titers and Geometric Mean Titers Ratio) of inactivated polio vaccine (IPV) after the booster vaccination", 
                "safety_issue": "No", 
                "time_frame": "Day 0 (pre-vaccination) and Day 28 post-booster vaccination"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi Pasteur, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}